Stock quote - News

AstraZeneca
AZN: 6,411.00 +80.00 ( +1.26 %) delayed: 17:34PM


  • FTSE regains its poise by lunchtime
    Monday 15 Jul 2019 12:07

    The FTSE 100 was up by midday, advancing 0.2% to 7,520.77 after slipping into the red earlier. Investors apparently focused on the positive elements of China's latest growth figures, announced overnight. Retailers were in the doghouse after weak industry figures and insurance stocks also took...
    Read more

  • UK stocks open slightly higher after mixed Chinese economic data
    Monday 15 Jul 2019 08:57

    UK stocks opened slightly higher on Monday after the release of a mixed set of Chinese data that showed economic growth slowing but better-than-expected industrial output and retail sales. At 0850, the benchmark FTSE 100 index was up 3.29 points at 7.509.26. Sports Direct International sank 12%...
    Read more

  • AstraZeneca's Type-1 diabetes treatment fails to get FDA approval
    Monday 15 Jul 2019 07:42

    AstraZeneca said the U.S. Food and Drug Administration had decided against approving the company's application for its diabetes drug. The drugmaker said it would work closely with the FDA to discuss the next steps after receiving a complete response letter from the US health regulator declining...
    Read more

  • AstraZeneca's lung cancer treatment granted Orphan Drug Designation
    Friday 12 Jul 2019 07:43

    AstraZeneca said the US Food and Drug Administration had granted Orphan Drug Designation to its treatment of small cell lung cancer. The FDA grants Orphan Drug Designation status to medicines and potential new medicines intended for the treatment, diagnosis or prevention of rare diseases or...
    Read more

  • Broker Forecast - Deutsche Bank issues a broker note on AstraZeneca PLC
    Monday 08 Jul 2019 09:10

    Deutsche Bank today reaffirms its buy investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 6900p (from 6800p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
    Read more

  • FTSE closes higher as S&P 500 hits new record
    Monday 01 Jul 2019 16:59

    The FTSE 100 closed up 1% at 7,497.50 as in the US the S&P 500 index hit new record levels. Amid a sea of green, China-related stocks were particularly in favour with JPMorgan Chinese Investment Trust up 7.7% amid optimism on trade relatons between the US and China in the wake of the G20...
    Read more

  • AstraZeneca receives positive opinion from European regulators to add self-administration option to asthma drug
    Monday 01 Jul 2019 08:47

    AstraZeneca said European health regulators issued a positive opinion to add a self-administration option for its asthma drug, inching the company closer to offering the treatment in a more convenient to many patients. 'The positive opinion for self-administration and the Fasenra pen is...
    Read more

  • AstraZeneca's type-2 diabetes drug receives positive opinion from European regulators for cardiovascular outcomes
    Monday 01 Jul 2019 08:17

    AstraZeneca said European regulators had delivered a positive opinion on the cardiovascular outcomes of its type-2 diabetes treatment that would see even more people benefit from the drug. The European Medicines Agency's Committee for Medicinal Products for Human Use had recommended a...
    Read more

  • FTSE 100 reverses gains amid growing nervousness as key summit gets underway
    Thursday 27 Jun 2019 12:19

    With the G20 leaders' summit getting underway European markets were tentative as they watched for progress on trade relations between the US and China. The FTSE 100, also hit by several stocks trading ex-dividend, fell 0.3% to 7,391.43 by midday. US futures pointed to a lower open on Wall...
    Read more

  • UK stocks rise ahead of G20 summit
    Thursday 27 Jun 2019 09:33

    UK stocks are rising this morning ahead of this weekend's G20 summit, which starts on Friday, and US President Donald Trump's meeting with Chinese premier Xi Jinping amid hopes of a resolution to the ongoing trade dispute. At 08:58, the benchmark FTSE 100 was seen up 0.18%, or 13.46 points, at...
    Read more

  • AstraZeneca says lung cancer drug met primary goal
    Thursday 27 Jun 2019 07:56

    AstraZeneca said its small cell lung cancer drug had met its primary goal as it showed a 'clinically-meaningful' improvement in survival rates of patients suffering from the disease compared with chemotherapy alone. A planned interim analysis conducted by an Independent Data Monitoring...
    Read more

  • FTSE slips as sterling surges on rate speculation
    Wednesday 19 Jun 2019 16:41

    The FTSE 100 closed down 0.5% at 7,403.54 as the pound was lifted by rumours of interest rate hikes later this year as the Bank of England prepares to meet tomorrow. With the US Federal Reserve set to outline their own rate call later, the S&P 500 was broadly flat by 4.30pm UK time....
    Read more

  • Stocks marking time until crunch Fed meeting
    Wednesday 19 Jun 2019 12:12

    The FTSE 100 was down 0.2% by midday at 7,425.62 as investors awaited the latest decision of the US Federal Reserve. US futures markets also pointed to a subdued open on Wall Street. Magazine publisher Future fell 10%, adding to heavy losses yesterday, following Monday night's publication of a...
    Read more

  • AstraZeneca, Merck ovarian cancer drug wins approval from Japanese regulators
    Wednesday 19 Jun 2019 07:23

    AstraZeneca and Merck said Japanese regulators had approved their ovarian cancer drug as a front-line therapy following positive clinical trial results. The approval by the Japanese Ministry of Health, Labour and Welfare was based on data from the pivotal Phase III SOLO-1 trial which tested...
    Read more

  • AstraZeneca's lung disease treatment gets regulatory nod in Japan
    Wednesday 19 Jun 2019 07:16

    AstraZeneca said its lung disease drug had been approved in Japan as dual and triple combination therapies to be used in a pressurised metered-dose inhaler to relieve symptoms in patients with chronic obstructive pulmonary disease. The approval of approval of the company's lung disease drug...
    Read more

  • Markets in risk-on mode after Draghi, Trump interventions and ahead of Fed meeting
    Tuesday 18 Jun 2019 16:41

    The FTSE 100 joined in a rally in global stocks as Mario Draghi hinted at further stimulus for the Eurozone economy, Donald Trump flagged an encouraging phone call with his Chinese counterpart amid ongoing trade tensions between the two countries and as investors awaited the latest decision from...
    Read more

  • Draghi gives stocks a big lift
    Tuesday 18 Jun 2019 12:17

    Hints of fresh stimulus for the Eurozone economy from European Central Bank chief Mario Draghi helped perk up markets on Tuesday. By midday the FTSE 100, which had traded modestly lower early on was up 0.8% at 7,414.62. In the US, where all eyes are on the Federal Reserve's rate decision...
    Read more

  • UK stocks open flat as investors brace for key interest rate decisions
    Tuesday 18 Jun 2019 08:59

    UK stocks opened flat on Tuesday as investors braced for key interest rate decisions due this week from both the Federal Reserve and the Bank of England. At 0855, the FTSE 100 was up 0.31 points at 7.357.62. Equipment rental group Ashtead gained 0.6%, as its annual profits jumped by a fifth on...
    Read more

  • AstraZeneca, Merck ovarian cancer drug gets regulatory nod in EU
    Tuesday 18 Jun 2019 07:16

    AstraZeneca and Merck said the European Commission had approved ovarian cancer drug as a front-line therapy following positive clinical trial results. The European Commission approval was based on data from the pivotal Phase III SOLO-1 trial which tested the cancer drug, Lynparza, as...
    Read more

  • AstraZeneca's leukaemia drug 'significantly' improves survival rates
    Monday 17 Jun 2019 07:16

    AstraZeneca said interim analysis of the phase III Ascent trial showed that its chronic lymphocytic leukaemia drug had significantly prolonged the time patients live without the disease. An encouraging 88% of patients on AstraZeneca's Calquence remained free of disease progression after 12...
    Read more

  • FTSE 100 momentum builds ahead of ECB meeting
    Thursday 06 Jun 2019 12:09

    The FTSE 100 was up 0.7% by midday to 7,269.84 as the market hoped for a market-friendly steer from the European Central Bank at its meeting later. This helped it shrug off several stocks trading ex-dividend including housebuilder Taylor Wimpey down 1.6%. LARGE AND MID CAP RISERS AND FALLERS...
    Read more

  • UK stocks rise on Wall Street gains ahead of ECB meeting
    Thursday 06 Jun 2019 09:28

    UK stocks are climbing on Thursday ahead of the European Central Bank meeting later in the session, buoyed by gains in the US overnight. At 08:58, the benchmark FTSE 100 was 0.52%, or 37.39 points, higher at 7,257.61. Auto Trader slipped 1.12% despite delivering annual results that topped...
    Read more

  • AstraZeneca chronic lymphocytic leukaemia drug meets primary goal
    Thursday 06 Jun 2019 07:47

    AstraZeneca said its results from a clinical trial assessing the company's chronic lymphocytic leukaemia drug had met its primary goal showing improved survival rates compared with the chemotherapy-based treatment. Calquence, the company's chronic lymphocytic leukaemia treatment, in...
    Read more

  • FTSE takes its cue from US recovery to get back in the black
    Monday 03 Jun 2019 16:38

    By the close the FTSE 100 had reversed earlier losses to trade 0.3% higher at 7,184.80 as US stocks showed signs of a fragile recovery from multi-month lows. UK manufacturing data showed activity levels in UK factories contracting as Brexit stockpiling ceased. Construction and outsourcing...
    Read more

  • AstraZeneca, Merck announce positive results from pancreatic cancer treatment
    Monday 03 Jun 2019 07:17

    AstraZeneca and Merck said more than a fifth of patients receiving treatment for pancreatic cancer remained free of disease progression after two years compared to just 10% on placebo. Results from the trial showed a statistically-significant and clinically-meaningful improvement in...
    Read more

  • Broker Forecast - Jefferies International issues a broker note on AstraZeneca PLC
    Friday 24 May 2019 09:10

    Jefferies International today reaffirms its hold investment rating on AstraZeneca PLC (LON:AZN) and cut its price target to 6350p (from 6400p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
    Read more

  • Broker Forecast - Barclays Capital issues a broker note on AstraZeneca PLC
    Friday 24 May 2019 09:00

    Barclays Capital today reaffirms its overweight investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 7200p (from 7000p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
    Read more

  • Broker Forecast - Deutsche Bank issues a broker note on AstraZeneca PLC
    Friday 10 May 2019 08:10

    Deutsche Bank today reaffirms its buy investment rating on AstraZeneca PLC (LON:AZN) and cut its price target to 6800p (from 6900p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
    Read more

  • Director Deals - AstraZeneca PLC (AZN)
    Wednesday 08 May 2019 17:00

    Marc Dunoyer, Financial Director, bought 8,500 shares in the company on the 7th May 2019 at a price of 5800.00p. The Director now holds 283,218 shares. Story provided by StockMarketWire.com Director deals data provided by www.sharesmagazine.co.uk
    Read more

  • AstraZeneca, Daiichi Sankyo breast cancer treatment meets primary goal
    Wednesday 08 May 2019 08:24

    AstraZeneca and Daiichi Sankyo Company said their breast cancer treatment had met its primary goal after demonstrating a 'clinically-meaningful response' in patients with a more aggressive version of the disease and poorer prognosis.  The response rate in DESTINY-Breast01, as assessed by an...
    Read more

  • UK stocks open 0.2% lower after new Trump tariff threat
    Tuesday 07 May 2019 08:48

    UK stocks opened lower on Tuesday after Donald Trump threatened to raise tariffs on Chinese goods, while a stronger pound put pressure on British companies with offshore sales. At 0842, the FTSE 100 was down 12.72 points, or 0.2%, at 7.367.92. Domino's Pizza sagged 6.8% after it said its...
    Read more

  • AstraZeneca's leukaemia treatment meets primary goal
    Tuesday 07 May 2019 07:51

    AstraZeneca said its treatment for chronic lymphocytic leukaemia had met its primary goal delivering an improvement in the time patients live without disease progression compared to an alternative combination treatment. Results from a clinical trial showed a statistically-significant and...
    Read more

  • AstraZeneca oral treatment for type-2 diabetes gets regulatory nod in US
    Friday 03 May 2019 08:05

    AstraZeneca said its oral treatment to aid type-2 diabetic patients to manage blood glucose levels had received regulatory approval from the US Food and Drug Administration. The US Food and Drug Administration (FDA) had approved Qternmet XR - a once-daily, oral medicine compromised of...
    Read more

  • Director Deals - AstraZeneca PLC (AZN)
    Thursday 02 May 2019 16:25

    Philip Broadley, Non Executive Director, bought 520 shares in the company on the 30th April 2019 at a price of 5738.00p. The Director now holds 3,755 shares representing 0.00% of the shares in issue. Story provided by StockMarketWire.com Director deals data provided by www.sharesmagazine.co.uk
    Read more

  • Director Deals - AstraZeneca PLC (AZN)
    Thursday 02 May 2019 16:20

    Pascal Soriot, Chief Executive Officer, bought 17,100 shares in the company on the 29th April 2019 at a price of 5825.00p. The Director now holds 206,996 shares. Story provided by StockMarketWire.com Director deals data provided by www.sharesmagazine.co.uk
    Read more

  • Broker Forecast - Deutsche Bank issues a broker note on AstraZeneca PLC
    Thursday 02 May 2019 10:50

    Deutsche Bank today reaffirms its buy investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 6900p (from 6800p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
    Read more

  • Director Deals - AstraZeneca PLC (AZN)
    Wednesday 01 May 2019 15:00

    Philip Broadley, Non Executive Director, bought 520 shares in the company on the 30th April 2019 at a price of 5738.00p. The Director now holds 3,235 shares representing 0.00% of the shares in issue. Story provided by StockMarketWire.com Director deals data provided by www.sharesmagazine.co.uk
    Read more

  • Director Deals - AstraZeneca PLC (AZN)
    Wednesday 01 May 2019 15:00

    Pascal Soriot, Chief Executive Officer, bought 17,100 shares in the company on the 30th April 2019 at a price of 5825.50p. The Director now holds 189,896 shares. Story provided by StockMarketWire.com Director deals data provided by www.sharesmagazine.co.uk
    Read more

  • Broker Forecast - Deutsche Bank issues a broker note on AstraZeneca PLC
    Tuesday 30 Apr 2019 10:30

    Deutsche Bank today reaffirms its buy investment rating on AstraZeneca PLC (LON:AZN) and cut its price target to 6800p (from 6900p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
    Read more

  • FTSE back in the black by the close
    Monday 29 Apr 2019 16:46

    The FTSE 100 recovered its poise to trade 0.17% higher by the close at 7,440.66 with the US interest rate decision, trade talks and big corporate releases later this week all in focus. In the US, trading was off to a decent start with the parent of technology giant Google, Alphabet, poised to...
    Read more

  • FTSE's progress stalls as markets await Google-parent Alphabet's earnings
    Monday 29 Apr 2019 12:10

    The FTSE 100 surrendered earlier gains to trade 0.1% lower at 7,420.71 ahead of a busy week in terms of corporate and macro-economic news. In the US futures markets pointed to a positive start with the parent of technology giant Google, Alphabet, scheduled to report first quarter earnings....
    Read more

  • UK stocks nudge higher following positive US, China data
    Monday 29 Apr 2019 09:02

    UK stocks opened higher on Monday after positive US and Chinese economic data helped cool global growth fears. At 0853, the benchmark FTSE 100 index was up 11.79 points, or 0.2%, at 7.439.98. Miner and commodities trader Ferrexpo jumped 11% after it hit back against claims by its former auditor...
    Read more

  • AtraZeneca's ovarian cancer treatment receives positive opinion from European regulators
    Monday 29 Apr 2019 07:47

    AtraZeneca said European regulators had offered a positive opinion on it and partner MSD's treatment for ovarian cancer. The Committee for Medicinal Products for Human Use of the European Medicines Agency delivered a positive opinion on the cancer drug Lynparza and recommended it as a...
    Read more

  • AstraZeneca more than doubles profits in Q1 as newer cancer drugs boost growth
    Friday 26 Apr 2019 07:33

    AstraZeneca more than doubled pre-tax profits in the first quarter of the year as the continued success of its new medicines and emerging markets performance boosted product sales. For the 3 months to 31 March, pre-tax profits rose to $758m from $374m a year earlier as revenue rose 6% to...
    Read more

  • AstraZeneca, MSD advanced breast cancer treatment gets EU regulatory nod
    Wednesday 10 Apr 2019 07:14

    AstraZeneca and MSD said the European Commission had approved their drug to treat patients with advanced breast cancer. The approval was based on data from the phase III OlympiAD trial which tested Lynparza as a monotherapy for advanced/metastatic breast cancer - stage III and IV breast...
    Read more

  • Broker Forecast - Liberum Capital issues a broker note on AstraZeneca PLC
    Friday 05 Apr 2019 08:50

    Liberum Capital today reaffirms its hold investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 6400p (from 5800p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
    Read more

  • Director Deals - AstraZeneca PLC (AZN)
    Wednesday 03 Apr 2019 11:25

    Marc Dunoyer, Financial Director, bought 4,838 shares in the company on the 29th March 2019 at a price of 0.00p. The Director now holds 274,718 shares. NOTE: Vesting - net of shares withheld to meet tax liabilities etc. Story provided by StockMarketWire.com Director deals data provided by...
    Read more

  • Director Deals - AstraZeneca PLC (AZN)
    Wednesday 03 Apr 2019 11:25

    Pascal Soriot, Chief Executive Officer, bought 15,755 shares in the company on the 29th March 2019 at a price of 0.00p. The Director now holds 172,796 shares. NOTE: Vesting - net of shares withheld to meet tax liabilities etc. Story provided by StockMarketWire.com Director deals data provided...
    Read more

  • Broker Forecast - HSBC issues a broker note on AstraZeneca PLC
    Tuesday 02 Apr 2019 11:20

    HSBC today reaffirms its reduce investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 5180p (from 5140p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
    Read more

  • Broker Forecast - UBS issues a broker note on AstraZeneca PLC
    Tuesday 02 Apr 2019 09:50

    UBS today downgrades its investment rating on AstraZeneca PLC (LON:AZN) to sell (from neutral) and cut its price target to 5400p (from 5900p). Story provided by StockMarketWire.com Broker Forecasts data provided by www.sharesmagazine.co.uk
    Read more

Page 1 |

Risk warning: Remember the price of shares can go down as well as up, and you are not guaranteed to get back the amount that you originally invested.
Click here to read the full warning.